Company intelligence / Profile preview

MELEMA Pharma GmbH

Hamburg, Hamburg, Germanymelemapharma.de ↗

Ownership: Private
Development stage: Preclinical

Overview

Aviscumine has demonstrated an excellent safety profile in over three Phase I trials (>80 patients), one Phase I/II trial (16 patients), and a Phase II trial with metastatic melanoma patients. The most recent phase II study showed effectiveness in advanced metastatic melanoma with promising survival data and minimal serious adverse events.

Therapeutic areas: Oncology
Modalities: Biologicals (recombinant proteins)Natural compound derivatives (notably plant protein viscumine/aviscumine)
Industry: Biotech

Drug pipeline

1 asset

aviscumine

Partnerships

Collaborates with academic institutions and industry partners for drug development but no specific major pharma partnerships named publicly.

Beyond the preview

Go deeper on MELEMA Pharma GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MELEMA Pharma GmbH.